Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 554-558

  Rajappa, Senthil ^a   Varadpande, Lalit ^a   Paul, Tara ^a   Jacob, Rachel ^a   Digumarti, Raghunadharao ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Hasford score

Indexed keywords

IMATINIB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTROLLED STUDY; CYTOGENETICS; DEVELOPING COUNTRY; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EARLY CANCER; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; DEVELOPING COUNTRIES; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 39749097125     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701824585     Document Type: Article

References (17)

1. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N. and Deininger (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med, 355, pp. 2408-2417.
2. Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M. and Kluin-Nelemans (1998) (Writing Committee for the Collaborative CML Prognostic Factors Project Group). A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst, 90, pp. 850-858.
3. Deshmukh, C., Saikia, T., Bakshi, A., Amare-Kadam, P., Baisane, C. and Parikh, P. (2005) Imatinib mesylate in chronic myeloid leukemia: A prospective, single arm, nonrandomized study. J Assoc Physicians India, 53, pp. 291-295.
4. Usman, M., Syed, N. N., Kakepoto, G. N., Adil, S. N. and Khurshid, N. (2007) Chronic phase chronic myeloid leukemia: Response of imatinib mesylate and significance of sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India, 55, pp. 103-107.
5. Jacob, A., Bapsy, P. P., Govind, B. K. and Lokanatha D (2007) Imatinib mesylate in newly diagnosed patients with chronic myeloid leukemia. ASCO Annual Meeting Proceedings. J Clin Oncol, 25:18, p. 17521.
6. Zeba, A., Javaid, I., Mohammed, A. and Sarah, S. (2007) Treatment of chroinic myeloid leukemia in the imatinib era-perspective from a developing country. Cancer, 109, pp. 1138-1145.
7. Cortes, J. (2004) Natural history and staging of chronic myeloid leukemia. Hematol Oncol Clin N Am, 18, pp. 569-584.
8. Kantarjian, H. M., Sawyer, C., Hochhaus, A., Guilhot, F., Schiffer, C. and Gambacorti-Passerini, C. (2002) Hematologic and cytogenetic response to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med, 346, pp. 645-652.
9. Rosti, G., Martinelli, G. and Bassi, S. (2004) Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood, 103, pp. 2284-2290.
10. O'Brien, Guilhot, F., Larson, R. A., Gathmann, I. A., Baccarani, M., Cervantes, F. and Cornellisen, J. J. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med, 348, pp. 994-1004.
11. Kantarjian, H., Cortes, J. and O'Brien, S. (2004) Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon alpha. Blood, 104, pp. 1979-1988.
12. Lahaye, T., Riehm, B. and Berger, U. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer, 103, pp. 1659-1669.
13. Hughes, T. (2006) ABL kinase inhibitor therapy for CML: Baseline assessments and response monitoring. ASH Education Program Book Hematol, p. 213.
14. Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J. and Druker, B. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA, 103, pp. 2794-2799.
15. White, D. L., Saunders, V. A., Dang, P., Engler, J., Zannettino, A. C. and Cambareri, A. C. (2006) OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib; reduced OCT-1 activity is the cause of low in-vitro sensitivity to imatinib. Blood, 108, pp. 697-704.
16. Thomas, J., Wang, L. and Clark, R. E. (2004) Active transport of imatinib into and out of cells: Implications for drug resistance. Blood, 104, pp. 3739-3745.
17. Baccarrani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B. and Appelbaum, F. (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European leukemia network. Blood, 108, pp. 1809-1822.